These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26970151)

  • 41. 'I cry every day': experiences of patients co-infected with HIV and multidrug-resistant tuberculosis.
    Isaakidis P; Rangan S; Pradhan A; Ladomirska J; Reid T; Kielmann K
    Trop Med Int Health; 2013 Sep; 18(9):1128-1133. PubMed ID: 23837468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes.
    Mor Z; Goldblatt D; Kaidar-Shwartz H; Cedar N; Rorman E; Chemtob D
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1195-201. PubMed ID: 25216833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa.
    Heller T; Lessells RJ; Wallrauch CG; Bärnighausen T; Cooke GS; Mhlongo L; Master I; Newell ML
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):420-6. PubMed ID: 20202299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multidrug-resistant tuberculosis in New South Wales, Australia, 1999-2010: a case series report.
    Roberts-Witteveen A; Reinten T; Christensen A; Sintchenko V; Seale P; Lowbridge C
    Int J Tuberc Lung Dis; 2015 Jul; 19(7):850-6. PubMed ID: 26056113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.
    Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
    J Antimicrob Chemother; 2017 Jul; 72(7):1871-1879. PubMed ID: 28419314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa.
    Anastasis D; Pillai G; Rambiritch V; Abdool Karim SS
    Int J Tuberc Lung Dis; 1997 Jun; 1(3):220-4. PubMed ID: 9432367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era.
    Palacios E; Franke M; Muñoz M; Hurtado R; Dallman R; Chalco K; Guerra D; Mestanza L; Llaro K; Bonilla C; Sebastian J; Bayona J; Lygizos M; Anger H; Shin S
    Int J Tuberc Lung Dis; 2012; 16(3):348-54. PubMed ID: 22640448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.
    Mulu W; Mekonnen D; Yimer M; Admassu A; Abera B
    Afr Health Sci; 2015 Jun; 15(2):368-77. PubMed ID: 26124781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 'I'm fed up': experiences of prior anti-tuberculosis treatment in patients with drug-resistant tuberculosis and HIV.
    Furin J; Isaakidis P; Reid AJ; Kielmann K
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1479-84. PubMed ID: 25517815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
    Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.
    Chung-Delgado K; Guillen-Bravo S; Revilla-Montag A; Bernabe-Ortiz A
    PLoS One; 2015; 10(3):e0119332. PubMed ID: 25790076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
    Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
    J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of drug resistant TB among outpatients at an HIV/TB clinic in Lilongwe, Malawi.
    Barnett B; Gokhale RH; Krysiak R; Kanyemba C; Chikaonda T; Bokosi M; Mukuzunga C; Saidi F; Phiri S; Hoffman IF; Hosseinipour MC
    Trans R Soc Trop Med Hyg; 2015 Dec; 109(12):763-8. PubMed ID: 26626340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.
    Kapata N; Chanda-Kapata P; Bates M; Mwaba P; Cobelens F; Grobusch MP; Zumla A
    Trop Med Int Health; 2013 Nov; 18(11):1386-91. PubMed ID: 24033538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.
    Streicher EM; Müller B; Chihota V; Mlambo C; Tait M; Pillay M; Trollip A; Hoek KG; Sirgel FA; Gey van Pittius NC; van Helden PD; Victor TC; Warren RM
    Infect Genet Evol; 2012 Jun; 12(4):686-94. PubMed ID: 21839855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.
    Baghaei P; Tabarsi P; Dorriz D; Marjani M; Shamaei M; Pooramiri MV; Mansouri D; Farnia P; Masjedi M; Velayati A
    Am J Ther; 2011; 18(2):e29-34. PubMed ID: 20019591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.